StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about HRTX. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.91 | $0.91 | -0.01% | 1.8M |
| 05-15 | $0.93 | $0.85 | -8.60% | 2.0M |
| 05-18 | $0.85 | $0.86 | +1.11% | 1.6M |
| 05-19 | $0.86 | $0.85 | -1.38% | 2.0M |
| 05-20 | $0.86 | $0.85 | -1.70% | 2.1M |
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $34.71M | $154.90M | $114.32M | $76.10M |
Operating Income | $-4.76M | $-2.54M | $-2.58M | $1.52M |
Net Income | $-8.11M | $-20.20M | $-17.24M | $-2.38M |
EPS (Diluted) | $-0.04 | $-0.12 | $-0.11 | $0.00 |
Total Assets | $246.22M | $255.88M | $248.95M | $232.09M |
Total Liabilities | $237.08M | $241.54M | $234.06M | $259.35M |
Cash & Equivalents | $26.12M | $28.65M | $43.07M | $16.52M |
Free Cash Flow OCF − CapEx | $-1.93M | $-27.91M | $-18.72M | $-20.05M |
Shares Outstanding | 189.65M | 188.31M | 159.52M | 197.75M |